Different mechanisms can lead to the same altered HLA class I phenotype in tumors

Tissue Antigens

Volumn 69, Issue SUPPL. 1, 2007, Pages 259-263

  Rodriguez, T ^a   Aptsiauri, N ^a   Mendez R ^a   Jimenez, P ^a   Ruiz Cabello, F ^a,b   Garrido, F ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

Cancer diagnostics and therapy; Human leukocyte antigen class I; Immune escape; Molecular mechanism; Tumor

Indexed keywords

HLA ANTIGEN CLASS 1;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; BLADDER CANCER; CHROMOSOME LOSS; COLORECTAL CARCINOMA; CONFERENCE PAPER; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; MELANOMA; MOLECULAR MECHANICS; PHENOTYPE; PRIORITY JOURNAL; TUMOR IMMUNITY; TUMOR REJECTION;

ATP-BINDING CASSETTE TRANSPORTERS; CHROMOSOMES, HUMAN, PAIR 15; COLORECTAL NEOPLASMS; DOWN-REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LOSS OF HETEROZYGOSITY; MELANOMA; MICROSATELLITE REPEATS; PHENOTYPE; URINARY BLADDER NEOPLASMS;

EID: 34247185990     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2006.00776.x     Document Type: Conference Paper

References (38)

1. Dunn GP, Old LJ, Shreiber RD. Three Es of cancer immunoediting. Annu Rev Immunol 2004: 3: 991-8.
2. Lanier LL. NK cell recognition. Annu Rev Immunol 2005: 23: 225-74.
3. Diefenbach A, Raulet DH. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev 2002: 188: 9-21.
4. Festenstein H, Garrido F. MHC antigens and malignancy. Nature 1986: 322: 502-23.
5. Festenstein H. The biological consequences of altered MHC expression on tumours. Br Med Bull 1987: 43: 217-27.
6. Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001: 83: 117-58.
7. Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveilance of altered HLA class I phenotypes in human. Immunol Today 1997: 18: 89-95.
8. Real LM, Jimenez P, Kirkin A et al. Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient. Cancer Immunol Immunother 2001: 49: 621-8.
9. Paschen A, Mendez R, Jimenez P et al. Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 2003: 103: 759-67.
10. Maleno I, Cabrera CM, Cabrera T et al. Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics 2004: 56: 244-53.
11. Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 2000: 191: 961-76.
12. Garrido F, Cabrera T, Accola RS et al. HLA and cancer: 12th International Histocompatibility Workshop Study. In: Charron D, ed. HLA Genetic Diversity of HLA, Functional and Medical Implications. Paris, France: EDK Publisher, 1997, 445-53.
13. Cabrera T, Pedrajas G, Cozar JM et al. HLA class I expression in bladder carcinomas. Tissue Antigens 2003: 62: 324-7.
14. Cabrera T, Salinero J, Fernanadez MA, Garrido A, Esquivas J, Garrido F. High frequency of altered HLA class I phenotypes in laryngeal carcinomas. Hum Immunol 2000: 61: 499-506.
15. Maleno I, Lopez-Nevot MA, Cabrera T, Salinero J, Garrido F. Multiple mechanisms generate HLA altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother 2002: 51: 389-96.
16. Romero JM, Jimenez P, Cabrera T et al. Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int J Cancer 2005: 113: 605-10.
17. Cabrera T, Fernandez MA, Sierra A et al. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 1996: 50: 127-34.
18. Cabrera CM, Jimenez P, Cabrera T, Esparza C, Ruiz-Cabello F, Garrido F. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens 2003: 61: 211-9.
19. Vora AR, Rodgers S, Parker AJ, Start R, Rees RC, Murray AK. An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma. Br J Cancer 1997: 76: 836-44.
20. Cabrera T, Collado A, Fernandez MA et al. High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens 1998: 52: 114-23.
21. Feenstra M, Verdaasdonk M, van der Zwan AW, de Weger R, Slootweg P, Tilanus M. Microsatellite analysis of microdissected tumor cells and 6p high-density microsatellite analysis in head and neck squamous cell carcinomas with down-regulated human leukocyte antigen class I expression. Lab Invest 2000: 80: 405-14.
22. Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 2005: 117: 248-55.
23. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yanelli JR, Rosenberg SA. Loss of functional beta 2-microglobulin in metastatic melanoma from five patients receiving immunotherapy. J Natl Cancer Inst 1996: 88: 100-8.
24. Benitez R, Godelaine D, Lopez-Nevot MA et al. Mutations of the beta-2 microglobulin gene results in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 1998: 52: 520-9.
25. Feenstra M, Veltkamp M, van Kuik J et al. HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas. Tissue Antigens 1999: 54: 235-45.
26. Feenstra M, Rozemuller E, Duran K et al. Mutation in the beta 2m gene is not a frequent event in head and neck squamous cell carcinomas. Hum Immunol 1999: 60: 697-706.
27. Perez B, Benitez R, Fernandez MA et al. A new beta 2 microglobulin mutation found in a melanoma tumor cell line. Tissue Antigens 1999: 53: 569-72.
28. Chen HL, Gabrilovich D, Tampe R, Girgis KR, Nadaf S, Carbone DP. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet 1996: 13: 210-3.
29. Seliger B, Ritz U, Abele R et al. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 2001: 61: 8647-50.
30. Serrano A, Tanzarella S, Lionello I, et al. Reexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment. Int J Cancer 2001: 94: 243-51.
31. Nie Y, Yang G, Song Y et al. DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis 2001: 22: 1615-23.
32. Blanchet O, Bourge JF, Ziszner H et al. Altered binding of regulatory factors to HLA class I gene enhancer is enactive in tumorigenic cell lines lacking class I antigen expression. Proc Natl Acad Sci U S A 1992: 89: 3488-92.
33. Yoon SJ, Kang JO, Park JS, Kim NK, Heo DS. Reduced expression of MHC class I antigen in human cancer cell lines with defective LMP-7. Anticancer Res 2000: 20: 949-53.
34. Meissner M, Reichert TE, Kunkel M et al. Defects in the human leukocyte antigen class I antigen-processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 2005: 11: 2552-60.
35. Kaklamanis L, Townsend A, Doussis-Anagnostopoulou IA, Mortensen N, Harris AL, Gatter KC. Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am J Pathol 1994: 145: 505-9.
36. Seliger B, Maeurer MJ, Ferrone S. Antigen processing machinery breakdown and tumor growth. Immunol Today 2000: 21: 455-64.
37. Bennik JR, Anderson R, Bacik I et al. Antigen processing: where tumor-specific T-cell responses begin. J Immunother 1993: 14: 202-8.
38. Vitale M, Pelusi G, Taroni B et al. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res 2005: 11: 67-72.